XERIS BIOPHARMA HOLDINGS, INC. Payments to Acquire Investments
XERIS BIOPHARMA HOLDINGS, INC. (XERS) reported Payments to Acquire Investments of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireInvestments · last filed 2026-03-02
- XERIS BIOPHARMA HOLDINGS, INC. payments to acquire investments for the quarter ending 2025-12-31 was $0.00.
- XERIS BIOPHARMA HOLDINGS, INC. payments to acquire investments for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. payments to acquire investments for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. payments to acquire investments for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. payments to acquire investments for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- XERIS BIOPHARMA HOLDINGS, INC. payments to acquire investments for fiscal 2024 was $34.48M, a 21.16% decline from fiscal 2023.
- XERIS BIOPHARMA HOLDINGS, INC. payments to acquire investments for fiscal 2023 was $43.74M.
- XERIS BIOPHARMA HOLDINGS, INC. payments to acquire investments for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
| Period end | Payments to Acquire Investments 3 month | Payments to Acquire Investments 6 month | Payments to Acquire Investments 9 month | Payments to Acquire Investments 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $0.00 derived: sum of 2 quarters · filed 2026-03-02 | $0.00 derived: sum of 3 quarters · filed 2026-03-02 | $0.00 10-K · filed 2026-03-02 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2025-11-06 | $0.00 10-Q · filed 2025-11-06 | $0.00 derived: sum of 4 quarters · filed 2026-03-02 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $0.00 10-Q · filed 2025-08-07 | $0.00 derived: sum of 3 quarters · filed 2026-03-02 | $5.00M derived: sum of 4 quarters · filed 2026-03-02 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-08 | $0.00 derived: sum of 2 quarters · filed 2026-03-02 | $5.00M derived: sum of 3 quarters · filed 2026-03-02 | $10.00M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $5.00M derived: sum of 2 quarters · filed 2026-03-02 | $10.00M derived: sum of 3 quarters · filed 2026-03-02 | $34.48M 10-K · filed 2026-03-02 |
| 2024-09-30 | $5.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $10.00M derived: sum of 2 quarters · filed 2025-11-06 | $34.48M 10-Q · filed 2025-11-06 | $34.48M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | $5.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $29.49M 10-Q · filed 2025-08-07 | $29.49M derived: sum of 3 quarters · filed 2026-03-02 | $29.49M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | $24.49M 10-Q · filed 2025-05-08 | $24.49M derived: sum of 2 quarters · filed 2026-03-02 | $24.49M derived: sum of 3 quarters · filed 2026-03-02 | $24.49M derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $0.00 derived: sum of 2 quarters · filed 2026-03-02 | $0.00 derived: sum of 3 quarters · filed 2026-03-02 | $43.74M 10-K · filed 2026-03-02 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | $0.00 derived: sum of 2 quarters · filed 2024-11-08 | $43.74M 10-Q · filed 2024-11-08 | $43.74M derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $43.74M 10-Q · filed 2024-08-08 | $43.74M derived: sum of 3 quarters · filed 2025-03-06 | $43.74M derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-03-31 | $43.74M 10-Q · filed 2024-05-09 | $43.74M derived: sum of 2 quarters · filed 2025-03-06 | $43.74M derived: sum of 3 quarters · filed 2025-03-06 | $43.74M derived: sum of 4 quarters · filed 2025-03-06 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $0.00 derived: sum of 2 quarters · filed 2025-03-06 | $0.00 derived: sum of 3 quarters · filed 2025-03-06 | $0.00 10-K · filed 2025-03-06 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $0.00 derived: sum of 2 quarters · filed 2023-11-09 | $0.00 10-Q · filed 2023-11-09 | $12.24M derived: sum of 4 quarters · filed 2024-03-06 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $0.00 10-Q · filed 2023-08-08 | $12.24M derived: sum of 3 quarters · filed 2024-03-06 | $22.87M derived: sum of 4 quarters · filed 2024-03-06 |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-09 | $12.24M derived: sum of 2 quarters · filed 2024-03-06 | $22.87M derived: sum of 3 quarters · filed 2024-03-06 | $35.10M derived: sum of 4 quarters · filed 2024-03-06 |
| 2021-12-31 | $12.24M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06 | $22.87M derived: sum of 2 quarters · filed 2024-03-06 | $35.10M derived: sum of 3 quarters · filed 2024-03-06 | $43.02M 10-K · filed 2024-03-06 |
| 2021-09-30 | $10.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $22.86M derived: sum of 2 quarters · filed 2022-11-09 | $30.78M 10-Q · filed 2022-11-09 | $41.15M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $12.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $20.15M 10-Q · filed 2022-08-10 | $30.51M derived: sum of 3 quarters · filed 2022-08-10 | |
| 2021-03-31 | $7.92M 10-Q · filed 2022-05-11 | $18.29M derived: sum of 2 quarters · filed 2022-05-11 | ||
| 2020-12-31 | $10.37M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $101.77M 10-K · filed 2022-03-11 | ||
| 2020-09-30 | $91.41M 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |